Education
About Us
Working with TipRanks
Follow Us
Wave Life Sciences (WVE)
NASDAQ:WVE
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.25Last Year’s EPS
-0.24Same Quarter Last Year
Strong Buy
Based on 10 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 04, 2025
|% Change Since: -19.60%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted several positive developments, including advancements in clinical programs, a strong financial position, and innovative breakthroughs in RNA editing. However, there were notable challenges such as increased R&D expenses and a net loss for the year. The sentiment is overall positive due to the significant progress and potential of the pipeline.Company Guidance
During the Wave Life Sciences Fourth Quarter and Full Year 2024 Earnings Conference Call, significant progress was highlighted in their RNA medicines programs. Key metrics include revenues of $83.7 million for Q4 2024, an increase from $29.1 million in Q4 2023, and a full year net income of $29 million, compared to a net loss of $16.3 million in 2023. Research and development expenses rose to $44.6 million for Q4 2024 from $34.1 million in the prior year, driven by new programs. The company ended the year with $302.1 million in cash and cash equivalents, up from $200.4 million in 2023, providing a cash runway into 2027. Clinical advancements included completing enrollment in the first cohort for the obesity treatment WVE-007 and promising data for the AATD program WVE-006, showing potential as a front-line treatment.Positive Clinical Data and Pipeline Expansion
Wave Life Sciences announced positive data for its AATD, DMD, and HD clinical programs, derisked a new modality with RNA editing, and expanded its pipeline with high-impact programs.
Advancement of WVE-007 for Obesity
WVE-007, a GalNAc siRNA for obesity, advanced to the clinic and completed enrollment in the first cohort of the in-light clinical trial.
Strong Financial Position
The company ended the year with $302.1 million in cash and cash equivalents, an increase from $200.4 million the previous year, enabling funding operations into 2027.
Demonstrated RNA Editing in Humans
The Restoration clinical program showed the first-ever clinical demonstration of RNA editing in humans with WVE-006, showing an increase in AAT from baseline.
Progress in Huntington's Disease Treatment
WVE-003 showed potent and durable mutant huntingtin reductions and a statistically significant correlation with slowing of caudate atrophy in Huntington's disease.
---
WVE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
WVE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 04, 2025 | $10.05 | $11.23 | +11.74% |
| Nov 12, 2024 | $16.44 | $15.89 | -3.35% |
| Aug 08, 2024 | $5.98 | $5.74 | -4.01% |
| May 09, 2024 | $5.85 | $5.76 | -1.54% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Wave Life Sciences (WVE) report earnings?
Wave Life Sciences (WVE) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is Wave Life Sciences (WVE) earnings time?
Wave Life Sciences (WVE) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is WVE EPS forecast?
WVE EPS forecast for the fiscal quarter 2025 (Q1) is -0.25.
---
